Tag: oral

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

Praxis Precision Medicines Provides Vormatrigine Program Update

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure

JM Group Limited Provides Further Update Regarding Trading Halt of its Securities

Hong Kong, June 01, 2026 (GLOBE NEWSWIRE) -- JM Group Limited (NYSE American: JMG) (the “Company” or “JMG”), a Hong Kong-headquartered sourcing and wholesale solutions provider for a wide array of consumer products, today provided the following further updates regarding the Company’s response to the trading halt placed by the New York Stock Exchange (“NYSE”) and the relevant regulatory inquiries previously announced by the Company on February 2, 2026.

PurelyWHITE Deluxe Teeth Whitening Powder 2025 Report: Whiten Your Smile Instantly With Zero Sensitivity

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

Nabors Energy Transition Corp. II Announces Extension of Deadline to Complete Business Combination

HOUSTON, Aug. 15, 2025 /PRNewswire/ -- Nabors Energy Transition Corp. II (Nasdaq: NETD) ("NETD" or the "Company") announced that its board of directors has elected...

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

VEG ER for Pets Partners with VetRec to Advance AI-Powered Documentation Across Emergency Veterinary Care

Rent-to-Own Industry Generated $11.8 Billion in 2025 as 6.7 Million U.S. Households Seek Alternatives to Traditional Financing

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

/C O R R E C T I O N — Ranok Therapeutics/

Praxis Precision Medicines Provides Vormatrigine Program Update

JM Group Limited Provides Further Update Regarding Trading Halt of its Securities

PurelyWHITE Deluxe Teeth Whitening Powder 2025 Report: Whiten Your Smile Instantly With Zero Sensitivity

Nabors Energy Transition Corp. II Announces Extension of Deadline to Complete Business Combination

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

FLOWERS FOODS, INC. REPORTS SECOND QUARTER 2025 RESULTS

Tuniu Announces Unaudited Second Quarter 2025 Financial Results

So-Young Reports Unaudited Second Quarter 2025 Financial Results

Martello Reports Financial Results for the First Quarter of the 2026 Fiscal Year

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Explore

Press Releases

News & Opinion

Living

Others

Follow us